Hypothalamic Obesity
20
4
5
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 20 trials
100.0%
+13.5% vs benchmark
30%
6 trials in Phase 3/4
40%
4 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (20)
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
Tirzepatide in PWS, HO and GNSO
Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
Open-Label Study of Setmelanotide in Hypothalamic Obesity
Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study)
The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study
Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)
Intranasal Oxytocin in Hypothalamic Obesity
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
Neuromodulation for Hypothalamic Obesity
Effects of Exenatide on Hypothalamic Obesity
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
A Personalized Program of Physical Activity and Diet for Hypothalamic Obesity
Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy
Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage
A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients